Form 4: Vaxcyte SVP Mikhail Eydelman Reports Stock Option Exercise and Share Sales

Mikhail Eydelman, SVP, General Counsel & Corporate Secretary of Vaxcyte, Inc., exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On March 5, 2025, Mikhail Eydelman, SVP, General Counsel & Corporate Secretary of Vaxcyte, Inc., exercised stock options to acquire 5,000 shares of common stock at a price of $21.41 per share.
• Eydelman also sold 2,621 shares at a weighted average price of $70.388, 2,267 shares at a weighted average price of $71.066, and 112 shares at a price of $72.37.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on June 11, 2024.
• Following these transactions, Eydelman directly owns 41,620 shares of Vaxcyte common stock and holds options for 144,497 shares.

Sentiment

Score: 5

Explanation: This is a routine disclosure of insider trading activity. The sentiment is neutral as it simply reports transactions.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like officers and directors, trade their company's stock. These filings provide transparency into insider transactions and are closely watched by investors.

Stakeholder Impact

• Shareholders may be interested in insider trading activity as it can provide insights into management's view of the company's prospects.

Key Dates